Compelling evidence supports the consistent downregulation of SLC25A37 in individuals afflicted with major depressive disorder (MDD), heralding its potential utility as a biomarker for MDD diagnosis and a propitious target for subsequent therapeutic and diagnostic interventions (Huo et al. 2016). This evidence concerns the gene SLC25A37 and major depressive disorder.